

## Literaturverzeichnis

- Aberg L, Heiskala H, Vanhanen SL, Himberg JJ, Hosking G, Yuen A, Santavuori P. Lamotrigine therapy in infantile neuronal ceroid lipofuscinosis (INCL), *Neuropediatrics* 1997, **28**, 77-79
- Aberg L, Järvelä I, Rapola J, Autti T, Kirves Kari E, Lappi M et al. Atypical juvenile neuronal ceroid lipofuscinosis (JNCL, CLN3) with GROD-like inclusions in the autonomic nerve cells of the gut wall, *Acta Neuropathol* 1998, **95**, 306-312
- Aguas AP, Nunes JF, Ferreira AD, Vital JP. Neuronal ceroid-lipofuscinosis: ultrastructural study of lymphocytic dense bodies, *Neurology* 1980, **30**, 976-980
- Aicardi J. Management of the myoclonic epilepsies, in Procopis PG, Rapin I (eds.): International Review of Child Neurology Series: Epilepsy in Children. New York, *Raven Press* 1994, pp77
- Bate L, Gardiner M. Genetics of inherited epilepsies, *Epileptic Disord.* 1999, **1**, 7-19
- Batten FE. Cerebral degeneration with symmetrical changes in the maculae in two members of a family, *Trans Ophthalmol Soc UK* 1903, **23**, 386-390
- Berkovic SF, Andermann F, Andermann E, Carpenter S, Wolfe L. Kufs disease: clinical features and forms, *Am J Med Genet Suppl.* 1988, **5**, 105-109
- Berry-Kravis E, Sleat DE, Sohar I, Meyer P, Donnelly R, Lobel P. Prenatal testing for late infantile neuronal ceroid lipofuscinosis, *Ann Neurol.* 2000, **47**, 254-257
- Boustany RM, Alroy J, Kolodny EH. Clinical classification of neuronal ceroid-lipofuscinosis subtypes, *Am J Med Genet Suppl.* 1988, **5**, 47-58
- Carpenter S, Karpati G, Andermann F. Specific involvement of muscle, nerve, and skin in late infantile and juvenile amaurotic idiocy, *Neurology* 1972, **22**, 170-186
- Cervos-Navarro J, Artigas J, Perez-Canto A. Clinical and immunohistological findings in subependymomas of the spinal cord. *Verh Dtsch Ges Pathol* 1986, **70**, 376-379
- Ceuterick C, Martin JJ. Diagnostic role of skin or conjunctival biopsies in neurological disorders - an update, *J Neurol Sci* 1984, **65**, 179-191
- Cho S und Dawson G. Enzymatic and molecular biological analysis of palmitoyl protein thioesterase deficiency in infantile neuronal ceroid lipofuscinosis, *J Neurochem* 1998, **71**, 323-329
- Cho S, Dawson PE, Dawson G. Antisense palmitoyl protein thioesterase 1 (PPT1) treatment inhibits PPT1 activity and increases cell death in LA-N-5 neuroblastoma cells, *J Neurosci Res* 2000, **62**, 234-240
- Chow CW, Borg J, Billson VR, Lake BD. Fetal tissue involvement in the late infantile type of neuronal ceroid lipofuscinosis, *Prenat Diagn* 1993, **13**, 833-841
- Cotman SL, Vrbanac V, Lebel LA, Lee RL, Johnson KA, Donahue LR, Teed AM, Antonellis K, Bronson RT, Lerner TJ, MacDonald ME. *Cln3* knock-in mice with the common JNCL mutation exhibit progressive neurologic disease that begins before birth, *Hum Mol Genet* 2002, **11**, 2709-2721
- Cotton RGH und Scriver CR. Proof of "disease causing" mutation, *Hum Mut* 1998, **12**, 1-3
- Croopnick JB, Choi HC und Müller DM. The subcellular location of the yeast *Saccharomyces cerevisiae*

- homologue of the protein defective in the juvenile form of Batten disease, *Biochem Biophys Res Commun* 1998, **250**, 335-341
- Das AM, Jolly RD, Kohlschütter A. Dysregulation of mitochondrial ATP synthase in sheep with neuronal ceroid-lipofuscinosis (NCL), *Mol Genet Metab* 1999, **66**, 349-355
- de Vries BB, Kleijer WJ, Keulemans JL, Voznyi YV, Franken PF, Eurlings MC, Galjaard RJ, Losekoot M, Catsman-Berrevoets CE, Breuning MH, Taschner PE, van Diggelen OP. First-trimester diagnosis of infantile neuronal ceroid lipofuscinosis (INCL) using PPT enzyme assay and CLN1 mutation analysis, *Prenat Diagn* 1999, **19**, 559-562
- Duffy PE, Kornfeld M, Suzuki K. Neurovisceral storage disease with curvilinear bodies, *J Neuropath Exp Neurol* 1968, **27**, 351
- Dyken P, Krawiecki N. Neurodegenerative diseases of infancy and childhood, *Ann Neurol* 1983, **13**, 351-364
- Elleder M, Sokolova J, Hrebicek M. Follow-up study of subunit c of mitochondrial ATP synthase (SCMAS) in Batten disease and in unrelated lysosomal disorders, *Acta Neuropathol (Berl)* 1997, **93**, 379
- Fisher MP, Dingman CW. Role of molecular conformation in determining the electrophoretic properties of polynucleotides in agarose-acrylamide composite gels, *Biochem* 1971, **10**, 1895-9
- Gardiner M, Sandford A, Deadman M, Poulton J, Cookson W, Reeders S, Jokiahio I, Peltonen L, Eiberg H, Julier C. Batten disease (Spielmeyer-Vogt disease, juvenile onset neuronal ceroid-lipofuscinosis) gene (CLN3) maps to human chromosome 16, *Genomics* 1990, **8**, 387-390
- Goebel HH, Mole SE, Lake BD (eds.), *The ceroid lipofuscinoses (Batten Disease)*, Oxford: IOS Press 1999
- Golabek AA, Kida E, Walus M, Kaczmarek W, Michalewski M, Wisniewski KE. CLN3 protein regulates lysosomal pH and alters intracellular processing of Alzheimer's amyloid-beta protein precursor and cathepsin D in human cells, *Mol Genet Metab* 2000, **70**, 203-213
- Gonatas NK, Gambetti P, Baird H. A second type of late infantile amaurotic idiocy with multilamellar cytosomes, *J Neuropath Exp Neurol* 1968, **27**, 371
- Haltia M, Rapola J., Santavuori P. Infantile type of so-called neuronal ceroid-lipofuscinosis. Histological and electron microscopical studies, *Acta Neuropathol (Berl)* 1973 a, **26**, 157-170
- Haltia M, Rapola J, Santavuori P, Keranen A. Infantile type of so-called neuronal ceroid-lipofuscinosis. Part 2. Morphological and biochemical studies, *J Neurol Sci* 1973 b, **18**, 269-285
- Harden A, Pampiglione G, Picton-Robinson N. Electroretinogram and visual evoked response in a form of "neuronal lipidosis" with diagnostic EEG features, *J Neurol Neurosurg Psychiatry* 1973, **36**, 61-67
- Hentze MW, Kulozik AE. A perfect message: RNA surveillance and nonsense-mediated decay, *Cell* 1999, **96**, 307-310
- Hirvasniemi A, Lang H, Lehesjoki AE, Leisti J. Northern epilepsy syndrome: an inherited childhood onset epilepsy with associated mental deterioration, *J Med Genet* 1994, **31**, 177-182
- Horiguchi M, Miyake Y. Batten disease--deteriorating course of ocular findings, *Jpn J Ophthalmol* 1992, **36**, 91-96
- Janes RW, Munroe PB, Mitchison HA, Gardiner RM, Moel SE, Wallace BA. A model for Batten disease protein CLN3. functional implications from homology and mutations, *FEBS Lett* 1996, **399**, 75-77

- Järvelä I. Infantile neuronal ceroid lipofuscinosis (CLN1): linkage disequilibrium in the Finnish population and evidence that variant late infantile form (variant CLN2) represents a nonallelic locus, *Genomics* 1991, **10**, 333-337
- Järvelä I, Rapola J, Peltonen L, Puhakka L, Vesa J, Ammala P, Salonen R, Ryyanen M, Haring P, Mustonen A, et al. DNA-based prenatal diagnosis of the infantile form of neuronal ceroid lipofuscinosis (INCL, CLN1), *Prenat Diagn* 1991, **11**, 323-328
- Järvelä I, Schleutker J, Haataja L, Santavuori P, Puhakka L, Manninen T, Palotie A, Sandkuijl LA, Renlund M, White R, et al. Infantile form of neuronal ceroid lipofuscinosis (CLN1) maps to the short arm of chromosome 1, *Genomics* 1991, **9**, 170-173
- Järvelä I, Mitchison HM, Munroe PB, O'Rawe AM, Mole SE, Syvanen AC. Rapid diagnostic test for the major mutation underlying Batten disease, *J Med Genet* 1996, **33**, 1041-1042
- Järvelä I, Autti T, Lamminranta S, Aberg L, Raininko R, Santavuori P. Clinical and magnetic resonance imaging findings in Batten disease: Analysis of the major mutation (1.02-kb deletion), *Ann Neurol* 1997, **42**, 799
- Järvelä I, Sainio M, Rantamaki T, Olkkonen VM, Carpén O, Peltonen L, Jalanko A. Biosynthesis and intracellular targeting of the CLN3 protein defective in Batten disease, *Hum Mol Genet* 1998, **7**, 85
- Järvelä I, Lehtovirta M, Tikkanen R, Kyttälä A, Jalanko A. Defective intracellular transport of CLN3 is the molecular basis of Batten disease (JNCL), *Hum Mol Genet* 1999, **8**, 1091-1098
- Jolly RD, Kohlschütter A, Palmer DN und Walkley SU. The neuronal ceroid-lipofuscinoses (Batten Disease), *Advances in Cell Aging and Gerontology* 1999, **3**, 391-420
- Junaid MA, Pullarkat RK. Increased brain lysosomal pepstatin-insensitive proteinase activity in patients with neurodegenerative diseases, *Neurosci Lett* 1999, **264**, 157-160
- Junaid MA, Sklower Brooks S, Wisniewski KE, Pullarkat RK. A novel assay for lysosomal pepstatin-insensitive proteinase and its application for the diagnosis of late-infantile neuronal ceroid lipofuscinosis, *Clin Chim Acta* 1999, **281**, 169-176
- Katz ML, Siakotos AN, Gao Q, Freiha B, Chin DT. Late-infantile ceroid-lipofuscinosis: lysine methylation of mitochondrial ATP synthase subunit c from lysosomal storage bodies, *Biochim Biophys Acta* 1997, **1361**, 66-74
- Katz ML, Shibuya H, Liu PC, Kaur S, Gao CL, Johnson gs. A mouse gene knockout model for juvenile ceroid-lipofuscinosis (Batten disease), *J Neurosci Res* 1999, **57**, 551
- Kimura S und Goebel HH. Electron microscopic studies on skin and lymphocytes in early juvenile neuronal ceroid lipofuscinosis, *Brain Dev* 1987, **9**, 576-580
- Kitaguchi T, Wisniewski KE, Maslinski S, Maslinska D, Wisniewski TM, Kim KS. Beta-protein immunoreactivity in brains of patients with neuronal ceroid lipofuscinosis: ultrastructural and biochemical demonstration, *Neurosci Lett* 1990, **112**, 155-160
- Kohlschütter A, Laabs R, Albani M. Juvenile neuronal ceroid lipofuscinosis (JNCL): quantitative description of its clinical variability, *Acta Paediatr Scand* 1988, **77**, 867-872
- Kohlschütter A, Gardiner RM, Goebel HH. Human forms of neuronal ceroid-lipofuscinosis (Batten disease): Consensus on diagnostic criteria, *J Inherit Metab Dis* 1993, **16**, 241-244

- Kremmidiotis G, Lensink IL, Bilton RL, Woollatt E, Chataway TK, Sutherland GR, Callen DF. The Batten disease gene product (CLN3p) is a Golgi integral membrane protein, *Hum Mol Genet* 1999, **8**, 523-531
- Lake B, Cavanagh NPC. Early-juvenile Batten's disease: A recognizable sub-group distinct from other forms of Batten's disease, *J Neurol Sci* 1978, **36**, 265
- Lauronen L, Munroe PB, Jävelä I, Autti T, Mitchinson HM, O'Rawe AM, Gardiner RM, Mole SE, Puranen J, Häkkinen AM, Kirveskari E, Santavuori P. Delayed classic and protracted phenotypes of compound heterozygous juvenile neuronal ceroid lipofuscinosis, *Neurol* 1999, **52**, 360
- Lee LG, Connell CR, Woo SL, Cheng RD, McArdle BF, Fuller CW, Halloran ND, Wilson RK. DNA sequencing with dyelabeled terminators and T7 DNAPolymerase: effect of dyes and NTPs on incorporation of dye-terminators and probability analysis of termination fragments, *Nucleic Acids Research* 1992, **20**, 2471-2483
- Lee RL, Johnson KR, Lerner TJ. Isolation and chromosomal mapping of a mouse homolog of the Batten disease gene *CLN3*, *Genomics* 1996, **35**, 617-619
- Levine AS, Lemieux B, Brunning R, White JG, Sharp HL, Stadlan E, Krivit W. Ceroid accumulation in a patient with progressive neurological disease, *Pediatrics* 1968, **42**, 583-591
- MacLeod PM, DC L, Nickel RE, Chang E, Nag S, Zonana J, Silvey K. Ultrastructural studies as a method of prenatal diagnosis of neuronal ceroid-lipofuscinosis, *Am J Med Genet* 1988, **5 (Suppl)**, 93
- Maquat LE, Carmicheal GG. Quality control of mRNA function, *Cell* 2001, **104**, 173-6
- McGeoch JE, Palmer DN. Ion pores made of mitochondrial ATP synthase subunit c in the neuronal plasma membrane and Batten disease, *Mol Genet Metab* 1999, **66**, 387-392
- Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells, *Nucl Acids Res* 1988, **16**, 1215
- Mitchison HM, Munroe PB, O'Rawe AM, Taschner PEM, de Vos N, Kremmidiotis G, Lensink I, *et al.* Genomic structure and complete nucleotide sequence of the Batten disease gene, *CLN3*, *Genomics* 1997, **40**, 346-350
- Mitchison HM, Bernard DJ, Greene ND, Cooper JD, Junaid MA, Pullarkat RK, de Vos N, *et al.* Targeted disruption of the *CLN3* gene provides a mouse model for batten disease, *Neurobiol Dis* 1999, **6**, 321
- Mole SE, Zhong N, Sarpong A, Logan WP, Hofmann SL, Franken PF, van Diggelen OP, Bruening MH, Moroziewicz DN. New Mutations in the neuronal ceroid lipofuscinosis genes, *Eur J Pediatr Neurol* 2001, **61**, 310-316
- Munroe PB, Rapola J, Mitchison HM, Mustonen A, Mole SE, Gardiner RM, Jarvela I. Prenatal diagnosis of Batten's disease, *Lancet* 1996, **347**, 1014-1015
- Munroe PB, Mitchison HM, O'Rawe AM, Anderson JW, Boustany RM, Lerner TJ, Taschner PE, de Vos N, Bruening MH, Gardiner RM, Mole SE. Spectrum of mutations in the Batten disease gene, *CLN3*, *Am J Hum Genet* 1997, **61**, 310-316
- Neitzel H. A routine method for the establishment of permanent growing lymphoblastoid cell lines, *Hum Genet* 1986, **73**, 320-326
- NIH. Cystagon to treat infantile neuronal ceroid lipofuscinosis, *National Institute of Health* 2001

- Palmer DN, Fearnley IM, Walker JE, Hall NA, Lake BD, Wolfe LS, Haltia M, *et al.* Mitochondrial ATP synthase subunit c storage in the ceroid-lipofuscinoses (Batten disease), *Am J Med Genet* 1992, **42**, 561
- Pampiglione G, Harden A. So-called neuronal ceroid-lipofuscinosis. Neurophysiological studies in 60 children, *J Neurol Neurosurg Psychiatry* 1977, **40**, 323
- Pearce DA und Sherman F. *btn1*, a yeast gene corresponding to the human gene responsible for Batten's disease, is not essential for viability, mitochondrial function, or degradation of mitochondrial ATP synthase, *Yeast* 1997, **3**, 691-7
- Pearce DA und Sherman F. A yeast model for the study of Batten disease, *Proc Natl Acad Sci USA* 1998, **95**, 6915-8
- Pearce DA, Nosel SA, Sherman F. Studies of pH regulation by Btn1p, the yeast homolog of human Cln3p, *Mol Genet Metab* 1999, **66**, 320-323
- Puranam KL, Guo WX, Qian WH, Nikbakht K, Boustany RM. CLN3 defines a novel antiapoptotic pathway operative in neurodegeneration and mediated by ceramide, *Mol Genet Metab* 1999, **66**, 294-308
- Purpura DP und Suzuki K. Distortion of geometry and formation of aberrant synapses in neuronal storage disease, *Brain Res* 1976, **116**, 1-21
- Ranta S, Zhang Y, Ross B, Lonka L, Takkunen E, Messer A, Sharp J, Wheeler R, Kusumi K, Mole SE, Liu W, Soares MB, Bonaldo MF, Hirvasniemi A, de la Chapelle A, Gilliam TC, Lehesjoki AE. The neuronal ceroid lipofuscinoses in human EPMR and *mnd* mutant mice are associated with mutations in CLN8, *Nat Genet* 1999, **23**, 233-236
- Rapola J, Santavuori P, Heiskala H. Placental pathology and prenatal diagnosis of infantile type of neuronal ceroid-lipofuscinosis, *Am J Med Genet* 1988, **5 (Suppl.)**, 99-103
- Rawlings ND, Barrett AJ. Tripeptidyl-peptidase I is apparently the CLN2 protein absent in classical late-infantile neuronal ceroid lipofuscinosis, *Biochem Biophys Acta* 1999, **1429**, 496
- Sachs B. A family form of idiocy, generally fatal and associated with early blindness (amaurotic family idiocy), *NY Med J* 1896, **63**, 697-703
- Sanger T, Nicklen S, Coulson AR. DNA sequencing with chain termination inhibitors, *Proc Natl Acad Sci USA* 1977, **74**, 5463-5467
- Santavuori P, Haltia M, Rapola J, Raitta C. Infantile type of so-called neuronal ceroid-lipofuscinosis. Part I. A clinical study of 15 patients. *J Neurol Sci* 1973, **18**, 257
- Savukoski M, Kestila M, Williams R, Järvelä I, Sharp J, Harris J, Santavuori P, Gardiner M, Peltonen L. Defined chromosomal assignment of CLN5 demonstrates that at least four genetic loci are involved in the pathogenesis of human ceroid lipofuscinoses, *Am J Hum Genet* 1994, **55**, 695-701
- Savukoski M, Klockars T, Holmberg V, Santavuori P, Lander ES, Peltonen L. CLN5, a novel gene encoding a putative transmembrane protein mutated in Finnish variant late infantile neuronal ceroid lipofuscinosis, *Nat Genet* 1998, **19**, 286-288
- Schriner JE, Yi W, Hofmann SL. cDNA and genomic cloning of human palmitoyl-protein thioesterase (PPT), the enzyme defective in infantile neuronal ceroid lipofuscinosis, *Genomics* 1996, **34**, 317-322. Erratum in: *Genomics* 1996, **38**, 458

- Schwendemann G, Colmant HJ, Elze KL, Koepp P, Lagenstein I, Steinhausen HC. Juvenile type of generalized ceroid-lipofuscinosis (Spielmeyer-Sjogren syndrome) II. Biopsy findings, *Neuropädiatrie* 1978, **9**, 28-48. Review
- Sharp JD, Wheeler RB, Lake BD, Savukoski M, Järvelä IE, Peltonen L, Gardiner RM, Williams RE. Loci for classical and a variant late infantile neuronal ceroid lipofuscinosis map to chromosomes 11p15 and 15q21-23, *Hum Mol Genet* 1997, **6**, 591-595
- Sleat DE, Donnelly RJ, Lackland H, Liu CG, Sohar I, Pullarkat RK, Lobel P. Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis, *Science* 1997, **277**, 1802
- Sohar I, Sleat DE, Jadot M, Lobel P. Biochemical characterization of a lysosomal protease deficient in classical late infantile neuronal ceroid lipofuscinosis (LINCL) and development of an enzyme-based assay for diagnosis and exclusion of LINCL in human specimens and animal models, *J Neurochem* 1999, **73**, 700-711
- Stengel C. Account of a singular illness among four siblings in the vicinity of Roraas. In: Armstrong D, Koppang N, Rider JA (eds), *Ceroid-lipofuscinosis (Batten's Disease)*. Elsevier Biomedical Press 1982 17-19. Translated from: Beretning om et mærkeligt Sygdomstilfoelde hos fire Sodskende i Naerheden af Roraas, *Eyr et medicinsk Tidsskrift* 1826, **1**, 347-352
- Syvanen AC, Järvelä I, Paunio T, Vesa J. DNA diagnosis and identification of carriers of infantile and juvenile neuronal ceroid lipofuscinoses, *Neuropediatrics* 1997, **28**, 63-66
- Tackmann W, Kuhlendahl D. Evoked potentials in neuronal ceroid lipofuscinosis, *Eur Neurol* 1979, **18**, 234-242
- Taschner PE, de Vos N, Breuning MH. Cross-species homology of the CLN3 gene, *Neuropediatrics* 1997, **28**, 18-20
- Tayama M, O'Brien JS, Kishimoto Y. Distribution of saposins (sphingolipid activator proteins) in tissues of lysosomal storage disease patients, *J Mol Neurosci* 1992, **3**, 171
- The International Batten Disease Consortium. Isolation of a novel gene underlying Batten disease, CLN3, *Cell* 1995, **82**, 949-957
- Thompson JD, Higgins DG, Gibson TJ. Clustal W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice, *Nucleic Acids Research* 1994, **22**, 4673-4680
- Tyynelä J, Palmer DN, Baumann M, Haltia M. Storage of saposins A and D in infantile neuronal ceroid-lipofuscinosis, *FEBS Lett* 1993, **330**, 8
- Van Bagh K und Hortling H. Blodfynd vid juvenil amaurotisk idioti, *Nord Med* 1948, **38**, 1072
- van Diggelen OP, Keulemans JL, Winchester B, Hofman IL, Vanhanen SL, Santavuori P, Voznyi YV. A rapid fluorogenic palmitoyl-protein thioesterase assay: pre- and postnatal diagnosis of INCL, *Mol Genet Metab* 1999, **66**, 240-244
- Verkruyse LA, Hofmann SL. Lysosomal targeting of palmitoyl-protein thioesterase, *J Biol Chem* 1996, **271**, 15831
- Vesa J, Hellsten E, Verkruyse LA, Camp LA, Rapola J, Santavuori P, Hofmann SL, et al. Mutations in the palmitoyl protein thioesterase gene causing infantile neuronal ceroid lipofuscinosis, *Nature* 1995, **376**, 584

- Vines D, Warburton MJ. Purification and characterisation of a tripeptidyl aminopeptidase I from rat spleen, *Biochem Biophys Acta* 1998, **1384**, 233
- Vines D, Warburton MJ. Classical late infantile neuronal ceroid lipofuscinosis fibroblasts are deficient in lysosomal tripeptidyl peptidase I, *FEBS Lett* 1999, **443**, 131
- Vogt H. Über familiäre amaurotische Idiotie und verwandte Krankheitsbilder, *Mtschr Psychiat Neurol* 1905, **18**, 161-171
- Walker DR, Bond JP, Tarone RE, Harris CE, Makalowski W, Boguski MS, Greenblatt MS. Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features, *Oncogene* 1999, **18**, 211-8
- Walkley SU, Siegel DD, Dobrens K. Batten disease: a typical neuronal storage disease or a genetic neurodegenerative disorder characterized by excitotoxicity, *Neurodegenerative Diseases* 1996, (Fiskum G., ed.) 217-224. Plenum Press, New York
- Williams RE, Topcu M, Lake BD, Mitchell W, Mole SE. CLN7 Turkish variant late infantile NCL. In: Goebel HH, Mole SE, Lake BD (eds), *The Neuronal Ceroid Lipofuscinosis (Batten Disease)* 1999. Amsterdam: IOS Press pp114-116
- Williams RS, Lott IT, Ferrante RJ, Caviness VS. The cellular pathology of neuronal ceroid-lipofuscinosis, *Arch Neurol* 1977, **34**, 298-305
- Wisniewski KE, Madrid RE, Dambaska M, Rapin I, Pullarkat R, Sklower S. Spino-cerebellar degeneration with polyneuropathy associated with ceroid lipofuscinosis in one family, *J Child Neurol* 1988, **3**, 33-41
- Wisniewski KE, Rapin I, Heaney-Kieras J. Clinico-pathological variability in the childhood neuronal ceroid-lipofuscinoses and new observations on glycoprotein abnormalities, *Am J Med Genet* 1988, **5 (Suppl.)**, 27-46
- Wheeler RB, Sharp JD, Mitchell WA et al. A new locus for variant late neuronal ceroid lipofuscinosis – CLN7, *Mol Genet Metab* 1999, **66**, 337-338
- Zeman W. Disturbances of nucleic acid metabolism preceding delayed radionecrosis of nervous tissue, *Proc Natl Acad Sci USA* 1963, **50**, 626-30
- Zeman W und Dyken P. Neuronal ceroid-lipofuscinosis (Batten's Disease): relationship to amaurotic family idiocy?, *Pediatrics* 1969, **44**, 570-583
- Zeman W, Donahue S, Dyken P, Green J. The neuronal ceroid-lipofuscinosis (Batten-Vogt syndrome), in Vinken P, Gruyn G, (eds): *Handbook of Clinical Neurology* 1970, pp588
- Zeman W, Siakotos AN. The neuronal ceroid lipofuscinoses, *Academic Press* 1973, pp15
- Zhong N, Wisniewski KE, Kaczmarek AL, Ju W, Xu WM, Xu WW, McLendon L, Liu B, Kaczmarek W, Brooks SS, Brown WT. Molecular screening of Batten disease: identification of missense mutation (E295K) in the CLN3 gene, *Hum Genet* 1998, **102**, 57-62